ClinicalTrials.gg
Not yet recruitingNCT06999746Updated May 31, 2025

Device-Assisted Oropharyngeal Rehabilitation in Obstructive Sleep Apnea Patients Using Continuous Positive Airway Pressure

An interventional study of Control and Oropharyngeal Exercise in Obstructive Sleep Apnea, sponsored by National Cheng-Kung University Hospital. Not yet recruiting at 1 site in Taiwan. Open to participants aged 20 Years to 68 Years. Per ClinicalTrials.gov, last updated 2025-05-31.

Sponsored by National Cheng-Kung University Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Non-randomized
Ages
20 Years to 68 Years
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the effectiveness of device-assisted oropharyngeal rehabilitation (OPR) in improving upper airway muscle function and reducing obstructive sleep apnea (OSA) severity in adult patients diagnosed with OSA who are receiving continuous positive airway pressure (CPAP) therapy.

The main questions it aims to answer are:

  1. Does combining OPR with CPAP increase upper airway space volume compared to using CPAP alone?
  2. Does OPR improve tongue muscle strength, and is this improvement associated with reduced CPAP pressure requirements?
  3. Do patients receiving OPR (alone or combined with CPAP) show greater improvements in OSA severity and clinical symptoms compared to those receiving CPAP alone or no intervention? Researchers will compare four groups-Control, OPR-only, CPAP-only, and CPAP + OPR-to see if device-assisted OPR enhances treatment outcomes beyond CPAP alone.

Participants will:

  1. Be randomly assigned to one of four groups (Control, OPR-only, CPAP-only, CPAP+OPR).
  2. Perform home-based OPR exercises (30-45 minutes/session, 1-2 sessions/day, 3-5 days/week for 3 months) in the OPR and CPAP+OPR groups.
  3. Have their exercise monitored using a strength sensor, with intensity adjusted every 2-4 weeks during hospital visits.
  4. Undergo assessments before and after the intervention, including:

(1) Polysomnography for OSA severity, (2) CT and ultrasound for upper airway and tongue muscle structure, (3) Tongue muscle strength/endurance tests, (4) Sleep quality questionnaires, (5) CPAP usage and pressure reports.

Read the detailed description

Background: Obstructive sleep apnea (OSA) is a common respiratory disorder associated with various complications, including cardiovascular, metabolic, and cognitive issues. Continuous positive airway pressure (CPAP) therapy can effectively reduce sleep apnea events and decrease the incidence of related complications. However, studies have shown that approximately half of OSA patients attempting CPAP therapy either cannot tolerate CPAP at all or only partially comply with it. Oropharyngeal rehabilitation (OPR), which involves isometric and isotonic exercises, can enhance the muscle tone of the tongue, pharynx, and soft palate. OPR may serve as one of the treatment options for OSA. Nevertheless, there is limited literature exploring the combined treatment approach of CPAP and OPR.

Methods:This study will recruit 30 200 adult OSA patients, who will be divided into two four groups: Control, OPR, CPAP alone and CPAP+OPR. The OPR training in OPR and CPAP+OPR groups will consist of home-based exercises performed for 30-45 minutes per session, once 1-2 session a day, five 3-5 days a week, over a period of three months. The training will be monitored using a strength sensor, and the intensity of the exercises will be adjusted every two weeks month during hospital visits. Both CPAP and CPAP+OPR groups will continue to wear CPAP every night, while the control group will receive monthly sleep hygiene education. The severity of OSA, upper airway space, tongue muscle length/thickness, tongue muscle strength/endurance, sleep quality, and CPAP usage report will be assessed using polysomnography, computed tomography scans, sonography, tongue muscle function tests, sleep quality questionnaires, and CPAP mask pressure at baseline and after three months of treatment.

Expected outcomes:

  1. Compared to the group using only CPAP, the CPAP + OPR group will have an increased upper airway space volume after a 3-month follow-up. The upper airway space volume is negatively correlated with CPAP pressure and positively correlated with tongue muscle strength.
  2. After 3 months of OPR treatment, the CPAP + OPR group will show an increase in tongue muscle strength, which is negatively correlated with CPAP pressure.
  3. After 3 months of OPR treatment, both the OPR group and the CPAP+OPR group showed greater improvements in upper airway muscle function and greater reductions in obstructive sleep apnea severity and clinical symptoms compared to the control group and the CPAP group respectively.
02

Conditions studied

  • Obstructive Sleep Apnea
03

In context

Sleep Apnea, Obstructive

2,263 studies on the registry are indexed under Sleep Apnea, Obstructive; 465 are open to participants now.

This study's planned enrollment of 200 is above the median of 53 across 1,490 interventional studies indexed under Sleep Apnea, Obstructive.

Browse Sleep Apnea, Obstructive studies →

Lead sponsor

National Cheng-Kung University Hospital is the lead sponsor of 276 studies on the registry; 71 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 68 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 20 to 68 years
  • Newly diagnosed with mild to severe pure obstructive sleep apnea based on polysomnography

Exclusion criteria

Exclusion Criteria:

  • Severe allergic rhinitis
  • Sinusitis with nasal polyps
  • Adenoid hypertrophy
  • Bilateral tonsillar hypertrophy (Friedman grade ≥ III)
  • Lingual tonsil hypertrophy (Friedman grade ≥ III)
  • Body Mass Index (BMI) > 40
  • Alcohol or drug abuse within the past year
  • Pregnancy
  • Severe obstructive or restrictive pulmonary diseases
  • High-risk cardiovascular diseases during exercise (e.g., angina, myocardial infarction, heart failure, valvular heart disease)
  • History of central or peripheral neurological disorders that interfere with exercise prescription
  • Musculoskeletal or psychological disorders that interfere with exercise prescription
  • Other non-respiratory sleep disorders
  • Sleep disorders with concomitant central sleep apnea
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Sham comparator
    Sleep hygiene education

    Receive monthly sleep hygiene education

    Other: Control

  • Experimental
    Oropharyngeal rehabilitation

    Receive oropharyngeal rehabilitation training over three months

    Device: Oropharyngeal Exercise

  • Experimental
    Continuous positive airway pressure

    Receive continuous positive airway pressure

    Device: Continuous positive airway pressure

  • Experimental
    Continuous positive airway pressure and oropharyngeal rehabilitation

    Receive continuous positive airway pressure and oropharyngeal rehabilitation training for three months

    Device: Continuous positive airway pressure and oropharyngeal exercise

Interventions

  • OtherControl

    Sleep hygiene education

  • DeviceOropharyngeal Exercise

    Device-monitoring oropharyngeal exercise, 1-5 days a week for three months

  • DeviceContinuous positive airway pressure

    Continuous positive airway pressure, 1-5 days a week for three months

  • DeviceContinuous positive airway pressure and oropharyngeal exercise

    Continuous positive airway pressure and device-monitoring oropharyngeal exercise, 1-5 days a week for three months

06

What researchers measure

Primary outcomes

  1. Apnea-Hypopnea Index

    The apnea-hypopnea index will be obtained from the overnight Polysomnography (PSG) study. PSG will be performed in the sleep center of National Cheng Kung University Hospital. Less than 5 events/hour indicates normal; AHI between 5-14 events/hour indicates mild Obstructive Sleep Apnea(OSA); AHI between 15-30 events/hour indicates moderate OSA; and AHI more than 30 events/hour indicates severe OSA.

    Time frame: Baseline and 12 weeks post intervention

Secondary outcomes

  1. Tongue Muscle Strength

    The maximal muscle strength of genioglossus muscles using The Iowa Oral Performance Instrument (IOPI) system, model 2.2 (Northwest, Co., LLC, Carnation, WA, USA) (kPa)

    Time frame: Baseline and 12 weeks post intervention

  2. Tongue Muscle Endurance

    The endurance of the genioglossus muscles using The Iowa Oral Performance Instrument (IOPI) system, model 2.2 (Northwest, Co., LLC, Carnation, WA, USA) (in seconds).

    Time frame: Baseline and 12 weeks post intervention

  3. Pharyngeal Airway Volume

    Computer Tomography (CT) will be performed. The pharyngeal airway volume will be calculated from the hard palate to the epiglottis and the data will be presented in cm\^3. The minimum score is 0 and a higher score indicates greater in pharyngeal airway volume.

    Time frame: Baseline and 12 weeks post intervention

  4. Cross Section Area on the Tip of Epiglottis

    Computer Tomography (CT) will be performed. Cross section area on the tip of the epiglottis was measured and the data will be presented in cm\^2. The minimum score is 0 and a higher score indicates greater in the cross-sectional area of the region.

    Time frame: Baseline and 12 weeks post intervention

  5. Anterior to Posterior Distance on the Tip of the Epiglottis

    The distance between the anterior and posterior pharyngeal wall on the tip of the epiglottis will be measured and presented in cm. The minimal value will be 0 and the greater value indicates a greater distance between the anterior to posterior in this area.

    Time frame: Baseline and 12 weeks post intervention

  6. Lateral Distance on the Tip of Epiglottis

    The distance between the lateral distance on the tip of the epiglottis will be measured and presented in cm. The minimal value will be 0 and the greater value indicates a greater distance between the lateral wall.

    Time frame: Baseline and 12 weeks post intervention

  7. Sleep Quality

    Sleep quality will be measured using Pittsburgh Sleep Quality Index (PSQI).The total score ranges from 0 to 21 with a higher total score equal to or more than 5 indicating worse sleep quality.

    Time frame: Baseline and 12 weeks post intervention

  8. Daytime Sleepiness Level

    Epworth Sleepiness Score(ESS) will be used to measure the daytime sleepiness of OSA patients. The total score of ESS range from 0-24. A score greater than 10 indicates greater daytime sleepiness.

    Time frame: Baseline and 12 weeks post intervention

  9. Tongue Muscle Thickness

    Sonography will be performed over the participant's neck region to assess the changes in tongue muscle thickness during normal breathing and Müller's maneuver. The data on tongue thickness will be presented in millimeters. A greater value indicates a thicker in tongue.

    Time frame: Baseline and 12 weeks post intervention

  10. Median Pressure in Continuous Positive Airway Pressure

    The change in therapeutic CPAP pressure required to maintain airway patency will be assessed using CPAP usage reports. A reduction in required pressure is expected to indicate improved upper airway muscle tone and stability.

    Time frame: 1-week average pre intervention, 1-week average post intervention and 1-month average during intervention for 3 months

  11. Median Usage Hours of Continuous Positive Airway Pressure

    The average number of hours per night that participants use CPAP will be recorded from CPAP usage reports. Greater nightly usage is considered indicative of better compliance and treatment effectiveness.

    Time frame: 1-week average pre intervention, 1-week average post intervention and 1-month average during intervention for 3 months

07

Study locations

1 site
  • National Cheng Kung University Hospital
    Tainan, 704, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2025; primary completion for Dec 2028, 42 months later.

Of 511 non-industry interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 53. This study's planned 42 months is above that.

Counting every sponsor, half of 621 studies reached it within 26 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2025
First posted
May 31, 2025
StartEst.
Jun 15, 2025
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2029
Last update
May 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06999746
Responsible party
Sponsor
First posted
May 31, 2025
Start date
Jun 15, 2025 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
May 31, 2025

Study contacts

Chieh-Yu Liu, MS
Contact
chiehyu0506@gmail.com
+886-988-613-312
Ching-Hsia Hung, PhD
Contact
chhung@mail.ncku.edu.tw
+886-6-2353535 ext. 5939
Ching-Hsia Hung, PhD
principal investigator · National Cheng Kung University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion